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RESPONSE: AN INSIDIOUS DEPENDENCE
Dana Mackin, M.A.; Christopher Martin, M.D.; and Jill K. McGavin, Ph.D.
Jill McGavin: What struck me most in
the article (Budney et al., 2007) was the ref-
erence to the rise in treatment admissions
for primary marijuana dependence in the
last 10 years. An increase from 7 to 16
percent of treatment admissions is dramatic.
It makes me wonder what the next 10 or 15
years will bring. I’m anxious to go back and
review the numbers in our treatment admis-
sions for the past couple of years to see if
we’ve already started a shift that has gone
undetected.
Dana Mackin: I was relieved to see that Dr.
Budney and his coauthors addressed the
uniqueness of marijuana addiction. When
I first started reading their article, I was resist-
ant to the idea that marijuana causes depend-
ence, because when we think of addiction
we think of the extreme and striking con-
sequences of methamphetamine or alcohol
abuse. On the other hand, we see the occa-
sional person who has no problem dropping
alcohol or methamphetamine, but cannot
stop smoking pot.
McGavin: Marijuana dependence is usually
a co-occurring addiction and usually not
the more dramatic one. I work primarily
with  veterans.  On  average,  they  are 
in their 50s. About a third are primarily 
alcohol-dependent, a third primarily cocaine-
dependent, and a third primarily heroin-
or opioid-dependent. In only a few cases is
marijuana a primary dependency.
Christopher Martin: My experience is sim-
ilar. However, I do see a fair number of patients
for whom marijuana abuse is a primary issue.
Many of them are young adults who are
involved in daily cannabis abuse and are not
functioning well. They haven’t moved out
of their parents’ homes and are spending a
lot of their time alone, playing video games
and sitting around the house. 
Mackin:Marijuana dependence is definitely
an issue in our clients’ lives. Someone in
recovery who has a heroin or metham-
phetamine addiction is much more likely
to relapse after using pot or taking a drink.
A client of mine said, “You don’t relapse on
your drug of choice; you relapse with pot.
Smoke a joint, and 3 days later, you’ll have
a needle in your arm.” In short, once you
cut out your executive decision-making abil-
ity, relapse is right around the corner.
Martin:That’s consistent with studies with
animal models, which have shown that drugs
have cross-priming properties. Animals
addicted to one substance, when exposed
to another reinforcing drug, will relapse to
use of the original substance. All of these
drugs have similar effects on the mesolim-
bic dopamine system and the reward cir-
cuitry, and it’s not surprising that one pos-
itively reinforcing substance can make it
difficult to stay away from another.
McGavin:Also, if you’re hanging on the cor-
ner, you’re more likely to be passed some-
thing you shouldn’t be using.
Mackin: Right. It puts you back into the
environment, and you don’t learn to deal
with anxiety or craving for your primary
drug without the aid of an external sub-
stance. You’re repeating the same behavior
with a different substance.
Benign reputation, debilitating effects
Mackin: Marijuana’s worst feature is that it
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to be addressed very gently, because people
do not accept the idea that pot is a problem
for them. In fact, they often think pot helps
them. They say they use it to relieve depres-
sion, anxiety, chronic pain, insomnia—any
of a number of things.
Martin: Marijuana users can be difficult to
work with and tend to have little desire to
change. The young people we see with
primary marijuana dependence often have
been coerced to come to the clinic by their
parents. That poses challenges for us.
Mackin: My program has a 90-day absti-
nence requirement. I’ll say to my clients,
“You can go back to smoking pot; you just
have to wait 90 days.” They don’t see the
benefits of quitting at first, only the draw-
backs. Once they experience abstinence for,
say, 30 or 60 days, I can say, “What differ-
ences do you notice?” Some say, “I have
much more energy,” or “I’m not forget-
ting things all of the time,” or “I’m doing
better at work.” Others say, “I’m white-
knuckling it and having trouble sleeping,
but it’s great to know I can do it.” I can think
of only one or two clients who hated abstain-
ing after a month or 2 without marijuana.
However, they had real trauma issues. With-
out those dual diagnosis issues, almost invari-
ably, clients feel a lot better once they’ve been
off pot for 2 or 3 months.
Martin:I see that, too. We occasionally hear,
after a patient has been abstinent from mar-
ijuana for a while, that he or she feels bet-
ter in terms of energy and mood. When that
happens, it makes an impression on them.
McGavin: I see more subtle realizations in
our patients. The bottom line motivator in
the Veterans Administration treatment 
setting is access to resources. Most of the
resources we offer veterans—like housing
and jobs—are contingent upon completely
clean drug screens. Patients may not per-
ceive direct benefits from marijuana absti-
nence, but indirectly, they see that they’ve
been able to get housing and a job. As they
work toward their vocational goals and go
out on job interviews, they get real-life feed-
back: “Oops, I can’t have this job because
I’m going to test positive.” They recognize
that their marijuana use is preventing them
from having things they want very much.
Treatment efficacy and strategy
Martin:I was struck by the modesty of the
effects of the treatments for marijuana abuse
and dependence. It’s disheartening, but it
makes me look toward further advances and,
I hope, some pharmacological treatments
to help with cannabis abuse, like those we
have for other types of drug abuse. 
Mackin:Treatment success rates may reflect
the fact that patients’ lives change less dra-
matically when they abstain from marijuana
than when they quit other drugs. A lot of
my clients’ lives are messy, and they don’t
become that much less messy when they
stop smoking pot—as opposed to when they
stop abusing methamphetamine, for instance.
With marijuana, half of the people aren’t
able to stick with treatment, and half of those
who do stick with treatment relapse within
a year.
Martin: In our work with our patients, we
use elements of cognitive-behavioral ther-
apy (CBT), as well as motivational enhance-
ment therapy (MET) and a 12-step model.
Also, as part of treatment, I try to find some-
thing to agree upon with my patients—
something about where they are in their lives
and where they’d like to go. I try to get them
to talk about some goals they have—for
instance, to go to school or to have a job.
We may be able to form an alliance based
on these goals; then we can look at what’s
getting in their way and try to build some
insight and motivation. Sometimes we make
progress that way.
Mackin:We focus on alcohol and metham-
phetamine issues, and marijuana comes
along for the ride. We base a lot of our treat-
ment models on motivational interviewing
and motivational enhancement. We use
CBT, MET, and contingency management.
We also use the Matrix Model, which is a
methamphetamine treatment program. 
McGavin: The early intervention, sec-
ondary prevention, and check-up programs
the authors discuss are very clever. We’ve
used similar interventions in our primary
care medical clinics with people who are
ambivalent about their alcohol use. In this
type of intervention, you can give basic
feedback about laboratory values, aver-
age numbers of drinks, and risks—similar
to the check-up intervention described
in the article. It might appeal especially to
youth. It’s interactive and could even be
presented online.
Martin:I agree. It’s a soft-sell approach that
allows us to step out of the power struggle
with patients. They’re the ones calling. 
They’re the ones inquiring. We just provide
them with the information we have, and
they decide what to do with it.
Mackin: Check-up style interventions
also help with retention. With our low socio-
economic status clients, and maybe crimi-
nally oriented ones, anything we can 
do to keep them coming to treatment is
important.
Martin: We also take advantage of the effect
patients can have on their peers. We have
about 24 inpatients. They often have sim-
ilar problems, but are at different stages of
motivation for change or of recovery.
Confrontation by their peers, or an ability
to relate to their peers or identify with them,
can help move patients along. Sometimes,
I think that’s more helpful than anything I
do for them.
Mackin:Peer pressure is always more effec-
tive than anything that I can say. Clients
look at me as “the Man” and “the govern-
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they’re not going to believe a word I say.
However, a peer turning to them and say-
ing, “I have gone through the same thing,
and here’s how it’s changed me,” hits home.
McGavin:I agree. Peers who are further into
recovery can provide some hope and say,
“I’ve been there and done that, and it worked
out for me. You just have to give it some
time.”
Mackin: Clients fill out a self-assessment
when they come into my program. They’re
all very resistant and say, “I don’t have a prob-
lem.” However, 10 or 12 weeks into treat-
ment, they fill out a second self-assessment.
Presumably, they’ve been learning, getting
insight, and going to Alcoholics Anonymous
or Narcotics Anonymous meetings. As part
of that second self-assessment, they must
talk with the group about what they’ve 
learned and any differences they’ve noticed
while they’ve been clean. The group gives
feedback. I try to be quiet and let them inter-
act with each other.
To strengthen this approach, I would
like to see some qualitative research inves-
tigating former marijuana abusers’ per-
ceptions about what treatment features made
the difference for them and what improve-
ments they saw in their lives. Armed with
such a study, I could talk to clients, and
instead of stating something anecdotally, I
could refer to this large-scale study.
McGavin: Over and over, contingency man-
agement is shown to be robust in the research
literature. It’s something we should all be
doing. But where do you get the money? It’s
foreign to our medical model to pay patients
to come to treatment. Could someone, some-
where, bill insurance for contingency man-
agement? It would make sense in the long
run, from a prosocial perspective. 
Mackin:We get a lot of government money,
and we run into the same old political argu-
ments: “You’re rewarding clients for things
that they’re supposed to do anyway.” Despite
its efficacy, contingency management is hard
to sell.
McGavin:I imagine any move to give patients
∆9-tetrahydrocannabinol (THC) to treat
their marijuana cravings, as discussed in the
article, would meet with massive resistance
from most of the treatment community
unless this intervention had been well val-
idated in solidly designed, large-scale stud-
ies. Even in such a case, I predict that admin-
istering THC as a part of a recovery program
would gain acceptance only very slowly.
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